The drugmaker said the results for giredestrant open the door to adding a treatment option at an early stage of the cancer, ...

Roche's experimental oral drug giredestrant has been shown to cut the risk of recurrence of a common form of breast cancer ...

The second-line endocrine therapy landscape in hormone receptor (HR)-positive, HER2-negative advanced breast cancer is ...

By embedding standardized questionnaires and algorithms into routine visits, providers can evaluate risk factors such as age, ...

The rationale is really strong since we're often making decisions for our patients based on single features or ...

Roche has reported another phase 3 win for its oral selective estrogen receptor degrader (SERD). Success at a planned interim ...

A real-world analysis of more than 60,000 patients in the US finds median survival increased by almost 7 months from 2011 to ...

Roche claimed the results make its drug giredestrant the first of its kind, a so-called oral SERD, to show a benefit in the ...

During a routine mammogram, doctors found something unusual in Patty Schone’s left breast. But the real danger was actually ...

A small group of women with advanced breast cancer participated in a trial where they received a vaccine, and all remain ...

A new law is providing better access to breast cancer screenings for Oklahomans. 2 News’ Naomi Keitt listened to experts to ...